Matthew W. Bending PhD, MSc, BSc (hons)

Matthew W. Bending

PhD, MSc, BSc (hons)

Dr. Matthew W. Bending is an experienced health economist with over 12 years consultancy experience and is Head of the HTA, Strategy and Communications team and Director of Real World Strategy & Analytics.

Matthew has led the development of early payer engagement services in Mapi and has experience of more than 25 HTA scientific advice engagements across a range of disease areas. Matthew provides senior leadership for large projects on strategic market access and Health Technology Assessments (HTAs) for pharmaceutical, vaccine, and medical device companies. His experience is wide-ranging, from projects for international HTA submissions, HTA scientific advice, value proposition development, market access, systematic literature reviews, economic models, payer advisory boards, and global value dossiers. Prior to joining Mapi, Matthew was a Senior Consultant at York Health Economics Consortium, working on projects for the National Institute for Health and Care Excellence, Department of Health, Patient Safety Research Portfolio, and more. Matthew has a PhD in Health Sciences from the University of York and his thesis explored the use of HTA in international reimbursement decision-making. He also has an MSc and BSc honours in Economics from the University of Warwick.

Matthew Bending completed a PhD fellowship on the use of Health Economic Analysis in OECD countries’ pharmaceutical systems and its contribution to decision-making. He has presented at international conferences, published over 30 reports/papers, and been involved in more than 100 HEOR and market access consulting projects. Dr. Bending was a co-author of a study that won the Egon Jonsson price in 2009/2010 for most outstanding paper published in the International Journal of Technology Assessment in Health Care: Trueman, P., Hurry, M., Bending, M. W. & Hutton, J. 2009. The feasibility of harmonizing health technology assessments across jurisdictions: A case study of drug eluting stents. International Journal of Technology Assessment in Health Care, 25, 455-462.

Employment History / Recent Positions

2014–Present, Director, Real World Strategy & Analytics

2013–2014, Associate Director, HEOR & Strategic Market Access

2013–2013, Sr. Research Manager, HEOR & Strategic Market Access

2012–2013, Research Manager

2011–2012, Senior Consultant
York Health Economics Consortium, University of York

2008–2011, Research Fellow
York Health Economics Consortium, University of York

2005–2008, Research Consultant
York Health Economics Consortium, University of York


University of York
2012 : Health Sciences : PhD

University of Warwick
2005 : Economics : MSc

University of Warwick
2004 : Economics : BSc (hons)


  • Wei C, Jarrett J, Ovcinnikov O, Bending MW. Are vaccines getting a fair deal? Health technology assessment of vaccines across Europe. 18th European Congress in Milan 2015 DOI:
  • De Silva SU, Dimova M, Bending MW. An Examination of the Regulatory and Reimbursement Processes,
    Conference Presentation.
    ISPOR 17th European Congress in Netherlands 2014 Open Archive DOI:
  • Smith TA, Silva De SU, Bending MW. How are Biosimilar Medicines Appraised as Health Technologies? An Evaluation of Appraisal Processes in Multiple Countries. 19th International Conference in Montreal Canada 2014 DOI:
  • Smith TA, De Silva SU, Firth ZA, Cuche MR, Bending MW. The Cost Implications of Renal Denervation Therapy at the Hospital Level in the United Kingdom. ISPOR 16th European Congress Dublin 2013 DOI:
  • De Silva SU, Smith TA, Bending MW. What are the Key Drivers of Reimbursement for Biosimilars? An Examination of Reimbursement Processes and Recommendations Across Nine Countries. Podium presentation, ISPOR 16th European Congress Dublin, 2013 DOI:
  • Bending MW, Smith A. Value and the Multiple Criteria used in OECD Countries’ Medicine Reimbursement Decision-Making processes using Health Economics Evidence. Value in Health Conference Abstract ISPOR November 2012.
  • Bending MW, Hutton J, McGrath C. 2012. A Comparison of Pharmaceutical Reimbursement Agencies’
    Processes and Methods in France and Scotland.
    International Journal of Technology Assessment in Health Care, Apr;28(2):187-94. DOI: 10.1017/S0266462312000104.
  • Beale S, Bending MW, Trueman P, Naidoo B. 2012. Should we invest in environmental interventions to encourage physical activity in England? An economic appraisal. European Journal of Public Health 2012 Dec;22(6):869-73. DOI: 10.1093/eurpub/ckr151. Epub 2012 Feb 24.